Business
Annual Report & Notice of AGM
Annual Report & Notice of AGM.
About this update from Gunsynd Plc
[{"type":"text","content":"\n Syntopix Group plc\n21 November 2006\n\n\nFor immediate release 21 November 2006\n\n\n\n\n\nSYNTOPIX GROUP PLC\n\n ('Syntopix' or 'the Company')\n\n\n\n ANNUAL REPORT AND NOTICE OF AGM\n\n\n\nSyntopix Group plc (AIM: SYN), the drug discovery and development company\nfocused on dermatological diseases, announces that, further to the preliminary\nresults announcement made on 28 September 2006, the Annual Report and Accounts\n2006 has now been posted to shareholders. It is also available on the Company's\nwebsite via the link www.syntopix.com/pdf/SyntopixAnnualReport2006.pdf .\n\nThe Annual Report includes notice of the Company's Annual General Meeting for\nshareholders, which will be held at 12pm on 12 December 2006 at the offices of\nWalker Morris, 12 King Street, Leeds LS1 2HL.\n\n\n\nFor further information please contact:\n\n\nSyntopix Group plc 0845 125 9204\nDarren Bamforth, Finance Director\nwww.syntopix.com\n\nKBC Peel Hunt Ltd 020 7418 8900\nMegan MacIntyre\n\nBuchanan Communications 020 7466 5000\nMark Court, Tim Anderson, Mary-Jane Johnson\n\n\n\n\n\nAbout Syntopix Group plc\n\nSyntopix Group plc began as a spin-out company from the University of Leeds.\nThe Syntopix strategy is designed to reduce the risks and costs of drug\ndevelopment by avoiding the use of new chemical entities. Flotation on AiM in\nMarch 2006 enabled the Company to take its first candidate products into the\ndevelopment pipeline. The Company's therapeutic focus is currently on acne and\nstaphylococcal skin infections. Syntopix has a collaborative approach and will\nwork with partners in the pharmaceutical and healthcare sector to expedite a\nrapid route to market.\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange \n ","length":2058,"tagName":"div"}]